Generic Name and Formulations:
Fluorometholone 0.1%; oph susp; contains benzalkonium chloride.
Indications for FML:
Adults and Children:
<2yrs: not recommended. ≥2yrs: 1 drop 2–4 times daily or small amount of ointment 1–3 times daily. May give every 4 hours for 1st 24–48 hrs. Reevaluate after 2 days.
Fungal, mycobacterial, viral (except herpes zoster), or untreated bacterial infections.
Corneal or scleral thinning. Glaucoma. Monitor for secondary infections and intraocular pressure in prolonged use. Avoid abrupt cessation. May mask or exacerbate infections. Pregnancy (Cat.C). Nursing mothers: not recommended.
Ocular irritation, increased intraocular pressure with possible glaucoma, infrequent optic nerve damage, cataracts, delayed wound healing; systemic hypercorticoidism (rare).
Susp—5mL, 10mL, 15mL; Oint—3.5g; Forte—5mL, 10mL, 15mL
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Nicotinamide and Cancer
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Opioid Prescription Protocol Decreases Opioid Use After Gynecologic Surgery
- Everolimus Plus Letrozole May Be Active in Recurrent Endometrial Carcinoma
- Affordable Care Act Increased Percentage of Insured Patients With Gynecologic Cancers
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML